Patents by Inventor W. Robb MACLELLAN

W. Robb MACLELLAN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220249623
    Abstract: An expression vector capable of disrupting the silencing of cell cycle genes in adult cells, such as adult cardiac myocytes and other quiescent cells in terminally differentiated tissues, comprising: (a) a nucleic acid sequence encoding lysine-specific demethylase 4D (KDM4D); (b) a promoter that induces or effects overexpression of KDM4D, wherein the promoter is operably linked to the nucleic acid sequence; and (c) a regulatory element that inducibly represses the overexpression of KDM4D. The vector can be administered to a subject in a method for inducing tissue-specific hyperplasia in a mammal, including cardiomyocyte proliferation. The method provides for regenerative therapy, including improving cardiac function after myocardial infarct and other forms of cardiac damage.
    Type: Application
    Filed: April 18, 2022
    Publication date: August 11, 2022
    Applicant: UNIVERSITY OF WASHINGTON
    Inventors: W. Robb MACLELLAN, Danny EL-NACHEF
  • Patent number: 11331377
    Abstract: An expression vector capable of disrupting the silencing of cell cycle genes in adult cells, such as adult cardiac myocytes and other quiescent cells in terminally differentiated tissues, comprising: (a) a nucleic acid sequence encoding lysine-specific demethylase 4D (KDM4D); (b) a promoter that induces or effects overexpression of KDM4D, wherein the promoter is operably linked to the nucleic acid sequence; and (c) a regulatory element that inducibly represses the overexpression of KDM4D. The vector can be administered to a subject in a method for inducing tissue-specific hyperplasia in a mammal, including cardiomyocyte proliferation. The method provides for regenerative therapy, including improving cardiac function after myocardial infarct and other forms of cardiac damage.
    Type: Grant
    Filed: April 20, 2016
    Date of Patent: May 17, 2022
    Assignee: UNIVERSITY OF WASHINGTON
    Inventors: W. Robb Maclellan, Danny El-Nachef
  • Publication number: 20180117125
    Abstract: An expression vector capable of disrupting the silencing of cell cycle genes in adult cells, such as adult cardiac myocytes and other quiescent cells in terminally differentiated tissues, comprising: (a) a nucleic acid sequence encoding lysine-specific demethylase 4D (KDM4D); (b) a promoter that induces or effects overexpression of KDM4D, wherein the promoter is operably linked to the nucleic acid sequence; and (c) a regulatory element that inducibly represses the overexpression of KDM4D. The vector can be administered to a subject in a method for inducing tissue-specific hyperplasia in a mammal, including cardiomyocyte proliferation. The method provides for regenerative therapy, including improving cardiac function after myocardial infarct and other forms of cardiac damage.
    Type: Application
    Filed: April 20, 2016
    Publication date: May 3, 2018
    Applicant: UNIVERSITY OF WASHINGTON
    Inventors: W. Robb MACLELLAN, Danny EL-NACHEF
  • Publication number: 20170108414
    Abstract: Methods and materials for high-resolution three-dimensional imaging of mammalian tissues, such as heart and intestine, are described. Both methods of tissue preparation for imaging and methods of imaging are described, as well as kits comprising materials and media for use in the methods.
    Type: Application
    Filed: October 20, 2016
    Publication date: April 20, 2017
    Applicant: UNIVERSITY OF WASHINGTON
    Inventors: W. Robb MACLELLAN, Danny EL-NACHEF